Abstract
PURPOSE: The recent introduction of the immune suppressor cyclosporin for treatment of steroid-refractory ulcerative colitis has required surgeons to perform a colectomy in those patients who eventually fail this rescue treatment, thus raising questions as to the safety of surgery as performed in patients with a heavily manipulated immune system. To assess the rates of mortality and morbidity in this setting, we studied a cohort of consecutive patients who had surgery after failing cyclosporin for refractory ulcerative colitis at our center. METHODS: Between January 1991 and December 1996, 25 patients with ulcerative colitis underwent restorative proctocolectomy performed in three steps (21 patients) and in two steps (4 patients). Seventeen of the 25 patients (68 percent) were initial nonresponders to a dose of 2 mg/kg/day of intravenous cyclosporin and underwent surgery immediately, the remaining 8 (32 percent) relapsed as outpatients on oral cyclosporin and were readmitted for surgery. RESULTS: There was no operative mortality. Nine patients of the 25 developed postoperative (early) complications (36 percent). The three-step operation subset had a 28 percent complication rate, the two-step 75 percent. Three patients needed reoperation. A total of 11 patients (44 percent) reported with late complications: two patients required surgical treatment, one for obstruction and one for pouch-perianal fistula. Three cases of pouchitis were recorded. No patient required pouch removal. CONCLUSION: Given the absence of postoperative mortality and a low overall complication rate, restorative proctocolectomy can safely be perofrmed in patients who fail rescue treatment with a dose of 2 mg/kg of cyclosporin for steroid-refractory ulcerative colitis. Corollary evidence in this article hints but does not prove that the three-step procedure is safer than the two-step operation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Penna C, Daude F, Parc R,et al. Previous subtotal colectomy with ileostomy and sigmoidostomy improves the morbidity and early functional results after ileal pouch anal anastomosis in ulcerative colitis. Dis Colon Rectum 1993;36:343–8.
Harms BA, Myers GA, Rosenfeld DJ, Starling JR. Management of fulminant ulcerative colitis by primary restorative proctocolectomy. Dis Colon Rectum 1994;37:971–8.
Ziv Y, Fazio VW, Church JM, Milsom JW, Schroeder TK. Safety of urgent restorative proctocolectomy with ileal pouch anal anastomosis for fulminant colitis. Dis Colon Rectum 1995;38:345–9.
Actis GC, Ottobrelli A, Pera A,et al. Continuously infused cyclosporin at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high dose steroids. J Clin Gastroenterol 1993;17(Suppl 1):10–3.
Sostegni R, Rocca G, Pinna-Pintor M, Actis GC, Rizzetto M. Combined immune modulation in refractory ulcerative colitis. A five year study [abstract]. Gut 1996;39:A75.
Lichtiger S, Present DH, Kornbluth A,et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–5.
Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum 1995;38:1241–5.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a clinical trial. BMJ 1955;2:1041–6.
Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open label retrospective trial. Inflamm Bowel Dis 1998;4:276–9.
Nicholls RJ, Lubowski DZ. Restorative proctocolectomy: the four loop (W) reservoir. Br J Surg 1987;4:564–6.
Utsunomiya J, Iwama T, Imajo M,et al. Total colectomy, mucosal proctectomy and ileoanal anastomosis. Dis Colon Rectum 1980;23:459–6
Segoloni GP, Messina M, Squiccimarro G. A diagnostic path in cyclosporin nephrotoxicity. In: Bonomini V, Scolari MP, Stefoni S, Vangelista A, eds. Biotechnology in renal replacement therapy. Basel: Karger, 1989:94–8.
Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996;91:423–33.
Sternthal M, George J, Kornbluth A, Lichtiger S, Present DH. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease [abstract]. Gastroenterology 1996;110:A1019.
Actis GC, Volpes R, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Cyclosporin for corticosteroid-refractory ulcerative colitis. Refinement of current treatment modalities. FALK Symposium No. 111, June 19–20, 1999. Lancaster: Kluwer Academic Publishers (in press).
Marcello PW, Roberts PL, Schoetz DJ. Long-term results of the ileo-anal pouch procedure. Arch Surg 1993;128:500–4.
Koltun WA, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. Dis Colon Rectum 1991;34:857–60.
Author information
Authors and Affiliations
About this article
Cite this article
Pinna-Pintor, M., Arese, P., Bona, R. et al. Severe steroid-unresponsive ulcerative colitis. Dis Colon Rectum 43, 609–613 (2000). https://doi.org/10.1007/BF02235571
Issue Date:
DOI: https://doi.org/10.1007/BF02235571